Oxaliplatin Fresenius Kabi

Oxaliplatin, the active ingredient in Oxaliplatin Fresenius Kabi, is a platinum-based antineoplastic agent presented as a sterile injectable solution for intravenous use. It is employed in the treatment of certain solid tumours, most notably colorectal cancer, and is administered under the supervision of oncology specialists. GNH USA supplies Oxaliplatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin is a platinum‑based chemotherapy used in the management of cancers that are treated with DNA‑damaging agents.

- Colorectal cancer: improves survival when combined with fluoropyrimidines in adjuvant or metastatic settings. - Gastric cancer: used in combination regimens for advanced disease. - Pancreatic cancer: incorporated into multi‑drug protocols for selected patients. - Ovarian cancer: employed in certain platinum‑sensitive relapse scenarios. - Small‑cell lung cancer: part of combination therapy for refractory cases. - Esophageal cancer: added to regimens for locally advanced disease.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: watery stools that may require antidiarrheal support. - Fatigue: generalized tiredness affecting daily activities. - Thrombocytopenia: reduced platelet count, increasing bleed risk. - Elevated liver enzymes: transient rise in ALT/AST.

Serious or Rare Side Effects: - Severe neutropenia: marked drop in neutrophils leading to infection risk. - Anaphylactic reactions: acute hypersensitivity requiring emergency care. - Pulmonary toxicity: interstitial lung changes causing breathing difficulty. - Cardiac arrhythmias: irregular heart rhythms observed in rare cases. - Hemolytic‑uremic syndrome: very rare renal and hematologic complication. - Stevens‑Johnson syndrome: severe skin and mucosal reaction.

Before initiating Oxaliplatin therapy, clinicians should assess patient suitability and monitor for potential complications.

- Renal function: evaluate creatinine clearance and adjust if impaired. - Hepatic function: check liver enzymes and bilirubin levels. - Pre‑existing neuropathy: assess baseline nerve function and consider dose modification. - Hematologic status: obtain baseline CBC to detect cytopenias. - Concomitant ototoxic drugs: avoid or monitor for additive hearing loss. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin can interact with several medicines, influencing efficacy or toxicity. Careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increase risk of neurotoxicity. - High‑dose vitamin C: may reduce platinum‑drug activity. - Live vaccines: immunosuppression can diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants: heightened bleeding risk due to thrombocytopenia.\n- NSAIDs: may exacerbate renal impairment. - CYP450 inducers: potential alteration of drug clearance. - Proton pump inhibitors: possible effect on gastrointestinal tolerance. - Anticonvulsants: may increase neurotoxic potential.